肠道在原发性硬化性胆管炎发病机制中的作用:证据与治疗启示
本文综述肠道因素在原发性硬化性胆管炎(PSC)发病机制中的证据。PSC与炎症性肠病相关,粪便及黏膜相关微生物研究显示PSC患者肠道菌群异常,可能通过改变肠道通透性、细菌或毒素经门脉循环至肝脏,引发免疫介导的胆管损伤;早期试验提示口服抗生素可能改善生化指标和症状。
要点
- PSC患者存在肠道菌群异常,可能与肝内胆管损伤相关。
- 肠道通透性改变可能促使细菌或毒素经门脉循环到达肝脏。
- 口服抗生素早期试验显示可改善PSC生化指标和症状。
核心结论
- 肠道菌群异常、肠道通透性改变及细菌/毒素门脉迁移可能参与PSC发病,早期抗生素试验支持肠道微生物调控的治疗潜力。
研究设计与样本
- 综述,检索已发表文献,评估肠道异常驱动PSC发生的机制证据及知识空白。
主要发现
- 粪便和黏膜相关微生物研究均显示PSC患者肠道菌群异常。
- 异常微生物产生的毒性副产物可能刺激免疫介导的肝细胞和胆管树损伤。
- 肠道通透性改变可能与细菌或相关毒素经门脉循环迁移至肝脏有关。
- 早期试验显示口服抗生素可改善PSC的生化参数和症状,推测通过调控肠道菌群实现。
关键数值与推荐
- 早期试验显示口服抗生素可改善PSC生化参数和症状(未报告具体数值)。
临床怎么用
- 提示临床可关注PSC患者肠道菌群及肠道屏障功能,但口服抗生素疗效需进一步验证。
局限性
- 综述指出相关机制证据尚不充分,存在知识空白,需未来研究验证通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa-associated microbial studies that patients with PSC harbor an abnormal enteric microbiome. These organisms are thought to produce toxic byproducts that stimulate immune-mediated damage of hepatocytes and the biliary tree. The link between these mechanisms may be related to altered intestinal permeability leading to migration of bacteria or associated toxins to the liver through the portal circulation. In support of these concepts, early trials have demonstrated improved biochemical parameters and symptoms of PSC with oral antibiotics, ostensibly through manipulation of the enteric microbiota. This article reviews the published literature for evidence as well as gaps in knowledge regarding these mechanisms by which intestinal aberrations might drive the development of PSC. We also identify areas of future research that are needed to link and verify these pathways to enhance diagnostic and therapeutic approaches.
引用
- Dean G, Hanauer S, Levitsky J, et al. The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. Hepatology. 2020. PMID: 32394535. doi:10.1002/hep.31311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。